Structure-based drug design and biological evaluation of 2-acetamidobenzothiazole derivative as EGFR kinase inhibitor

References

• Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 2004;44:195–217
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127–37
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002;110:669–72
   PubMed Web of Science ®Google Scholar
• Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997;8:1197–206
   PubMed Web of Science ®Google Scholar
• Tanno S, Ohsaki Y, Nakanishi K, et al. Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib (“Iressa”, ZD1839). Oncol Rep 2004;12:1053–7
   PubMed Web of Science ®Google Scholar
• Van der Veeken J, Oliveira S, Schiffelers RM, et al. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets 2009;9:748–60
   PubMed Web of Science ®Google Scholar
• Nguyen D, Yang SX. Epidermal growth factor expression in breast cancer. J Clin Oncol 2005;23:8118–41
   PubMed Web of Science ®Google Scholar
• Ma XH, Wang R, Tan CY, et al. Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines. Mol Pharm 2010;7:1545–60
   PubMed Web of Science ®Google Scholar
• Boschelli DH. Small molecule inhibitors of receptor tyrosine kinases. Drug Future 1999;24:515–37
   Google Scholar
• Xu YY, Li SN, Yu GJ, et al. Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity. Bioorg Med Chem 2013;21:6084–91
   PubMed Web of Science ®Google Scholar
• Bridges AJ. Chemical inhibitors of protein kinases. Chem Rev 2001;101:2541–72
   PubMed Web of Science ®Google Scholar
• Reck M, Zandwijk NV, Gridelli C, et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV tarceva lung cancer survival treatment study. J Thorac Oncol 2010;5:1616–22
   PubMed Web of Science ®Google Scholar
• Smith J. Erlotinib: small-molecule targeted therapy in the treatment of non-small cell lung cancer. Clin Ther 2005;27:1513–34
   PubMed Web of Science ®Google Scholar
• Tamura K, Fukuoka M. Gefitinib in non-small cell lung cancer. Expert Opin Pharmacother 2005;6:985–93
   PubMed Web of Science ®Google Scholar
• Grosdidier A, Zoete V, Michielin O. SwissDock, a protein-small molecule docking web service based on EADock DSS. J Comput Chem Nucleic Acids Res 2011;39:270–7
   PubMed Web of Science ®Google Scholar
• Mohd A, Asif S, Israr A, Mohd ZH. Synthesis of benzothiazole derivatives having acetamido and carbothioamido pharmacophore as anticonvulsant agents. Med Chem Res 2012;21:2661–70
   Web of Science ®Google Scholar
• Ma H, Deacon S, Horiuchi K. The challenge of selecting protein kinase assays for lead discovery optimization. Expert Opin Drug Discov 2008;3:607–21
   PubMed Web of Science ®Google Scholar
• Grever MR, Schepartz SA, Chabner BA. The National Cancer Institute: cancer drug discovery and development program. Semin Oncol 1992;19:622–38
   PubMed Web of Science ®Google Scholar
• Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Rev Res 1995;34:91–109
   Web of Science ®Google Scholar
• Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757–66
   PubMed Web of Science ®Google Scholar
• Nalbantsoy A, Karabay-Yavasoglu NU, Sayım F, et al. Determination of in vivo toxicity and in vitro cytotoxicity of venom from the Cypriot blunt-nosed viper Macrovipera lebetina lebetina and antivenom production. J Venom Anim Toxins Incl Trop Dis 2012;18:208–16
   Web of Science ®Google Scholar
• Turner R, ed. Quantal responses: calculation of ED50. In Screening methods in pharmacology. New York: Academic Press; 1965:61–3
   Google Scholar
• Wolber G, Langer T. LigandScout: 3D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Comp Sci 2005;45:160–9
   Google Scholar
• Omura S, Sasaki Y, Iwai Y, Takeshima H. Staurosporine, a potentially important gift from a microorganism. J Antibiot (Tokyo) 1995;48:535–48
   PubMed Web of Science ®Google Scholar
• Gescher A. Staurosporine analogues – pharmacological toys or useful antitumour agents? Crit Rev Oncol Hematol 2000;34:127–35
   PubMed Web of Science ®Google Scholar
• Yang S, Malaviya R, Wilson LJ, et al. Simplified staurosporine analogs as potent JAK3 inhibitors. Bioorg Med Chem Lett 2007;17:326–31
   PubMed Web of Science ®Google Scholar
• Kubo T, Yamamoto H, Lockwood W, et al. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer 2009;124:1778–84
   PubMed Web of Science ®Google Scholar
• Milenic D, Wong K, Baidoo K, et al. Cetumximab: preclinical evaluation of monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm 2008;23:619–31
   PubMed Web of Science ®Google Scholar
• Sahlberg S, Spiegelberg D, Lennartsson J, et al. The effect of a dimeric Affibody molecule (ZEGFR:19072) targeting EGFR in combination with radiation in colon cancer cell lines. Int J Oncol 2012;40:176–84
   PubMed Web of Science ®Google Scholar
• Ryan A, Wedge S. ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases, blocks VEGF-C-induced activation of VEGFR-3 and cell proliferation in human colon cancer cell lines. Br J Cancer 2005;92:S6–13
   PubMed Web of Science ®Google Scholar
• Xu H, Yu Y, Marciniak D, et al. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Mol Cancer Ther 2005;4:435–42
   PubMed Web of Science ®Google Scholar
• Reginato MJ, Mills KR, Paulus JK, et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 2003;5:733–40
   PubMed Web of Science ®Google Scholar